PathAI, a global provider of artificial intelligence-powered technology for use in pathology research has secured an investment from LabCorp, a leading global life sciences company. Financial terms were not disclosed. The investment will support PathAI’s efforts to expand clinical development of artificial intelligence-enabled computational pathology and advance its eventual integration with clinical laboratories. "As we continue to build on our early success in research toward faster and more accurate diagnosis and treatment of disease, our relationship with LabCorp could help bring these efforts to the market – and more importantly, to patients – more quickly and broadly.” Andy Beck, Co-founder and Chief Executive Officer of PathAl.